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The adrenergic system is a part of autonomic
nervous system, which regulates neuronal,
endocrine, metabolic and cardiovascular function.
Adrenergic receptors (ARs), the members of G-pro-
tein coupled receptors (GPCRs) superfamily, are
divided into three main classes α1, α2 and β. The
α1ARs are important mediators of sympathetic nerv-
ous system responses, particularly those involved in
cardiovascular homeostasis via arteriolar smooth
muscle constriction and cardiac contraction (1, 2).
Moreover, α1ARs have been implicated in the
pathogenesis of cardiac hypertrophy, in ischemia-
induced cardiac arrhythmias, and in ischemic pre-
conditioning (3). Cardiac arrhythmias are cardiac
rhythm disorders, which are significantly associated
with increased risks of cardiovascular complications
and sudden death. Atrial fibrillation (AF) is the most
common sustained arrhythmia. The number of peo-
ple suffering from this condition is expected to rise
due to the gradual ageing of societies; therefore it
seems to be an important epidemiological and pub-
lic health issue. The role of α1-ARs in various types
of arrhythmia has been investigated even though α1-
adrenergic agents are not considered in the
Vaughan-Williams classification of antiarrhythmic
drugs. Some studies revealed the antiarrhythmic
properties of α1-adrenoreceptor antagonists in the
case of ischemic arrhythmia (4, 5) and in this con-
text, in recent decades, various α1-adrenoreceptor
antagonists have been designed and synthesized. A
large group of adrenoreceptor antagonists are based
on an arylpiperazinyl moiety, a well-known phar-
macophore present in several classes of α1-AR lig-
ands. The large database of potent α1-adrenorecep-
tor antagonists with the example of urapidil, WAY-
100635, BMY-7378, REC-15/2739, RN5 (Fig. 1)
allowed to evaluate pharmacophore models of the
α1-antagonist (6-15). Among them, Barbaroís
model, especially useful for phenylpiperazine deriv-
atives, has postulated five pharmacophore features:
a positive ionizable atom (PI), three hydrophobic
regions (HY1ñHY3), and a hydrogen bond acceptor
(HBA) (14). The above-mentioned α1-adrenorecep-
tor antagonists possess an ortho-substituted phenyl
ring corresponding to PI atom and both HY1 and
HY2 regions, respectively. These compounds also
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contain an additional or fused aromatic moiety, ter-
minating the heterocyclic fragments, which can cor-
respond to the HY3-feature and they possess an
alkyl spacer of 2-7 carbons (14). Derivatives of this
type, called long-chain arylpiperazines (LCAPs)
form a widely explored class of bioactive com-
pounds, which is represented among others by the
group of the 5HT1A receptor ligands. The structural
features of LCAPs, which determine selectivity for
α1-adrenergic receptors over serotonin 5-HT1A are
not clear, due to a high degree of similarity in amino
acid sequence of receptors. 
On the other hand, case reports (16-19) suggest
that endogenous adenosine may cause clinically sig-
nificant arrhythmias in patients during acute
myocardial infarction, the sick sinus syndrome, car-
Scheme 1. Synthetic pathways of novel 1,3-dimethyl-(1H,8H)-imidazo[2,1-f]purine-2,4-dione derivatives (5-11).
Figure 1. Chemical structures of potent α1-AR antagonists
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diac arrest or cardiac transplant rejection. Based on
this fact adenosine receptors antagonists appear to
be effective in converting these arrhythmias to nor-
mal sinus rhythm (20). A large number of antago-
nists of the adenosine receptors have been devel-
oped in the group of xanthines, derived from the
natural alkaloids theophylline and caffeine.
Our previous studies were focused on cardio-
vascular activity of N-hydroxyamide, alkanolo-
amides, dialkylamino-alkylamides and some of
morpholinylalkylamides of pyrimidin-8-on[2,1-
f]theophylline-9-alkylcarboxylic acids (21). The
amide derivatives of alkylcarboxylic acids are sig-
nificantly represented in a group of drugs, used in
the treatment of cardiovascular disorders. These
compounds have been most frequently presented as
antiarrhythmic agents, which belong to I class
Vaughan-Williamís classification. Some derivatives
of pyrimidin-8-on[2,1-f]theophylline-9-alkylcar-
boxylic acids presented effects on arrhythmia and
blood pressure parameters. The most interesting
were dialkylamino-alkylamides and their morpho-
line analogs, which protected the heart against the
bradycardia and diminished mortality of animals
(21). 
Moreover, we carried out chemical modifica-
tion of phenytoin, a known anticonvulsant and
antiarrhythmic agent, in order to find out which
structural features influence on the antiarrhythmic
potency and decrease its anticonvulsant action (22).
Phenytoin (5,5-diphenyl-hydantoin) possessed
structural properties similar to known α1-AR antag-
onists but unlike them the selectivity of hydantoin
derivatives with LCAPs moiety (4, 23, 24) for 5-
HT1A receptor and α1-AR depends on the chain
length of the alkyl spacer between hydantoin and
piperazine and on the size of various substituents in
hydantoin core.
On the basis of our previous work (21, 22) and
taking into account the Barbaroís pharmacophore
model of the α1-antagonist, this paper reports further
structural modifications in the previously synthe-
sized series of LCAPs, in particular the introduction
of small alkylamine group into 1,3-dimethyl-
(1H,8H)-imidazo[2,1-f]purine-2,4-dione fragment
(Scheme 1). Moreover, the LCAPs derivatives, con-
taining 2-methoxy-phenylpiperazine moiety (struc-
tural element of urapidil), were designed in order to
gain a new insight into the structural requirements
that directly affect antiarrhythmic activity.
Furthermore, to determine the role of the terminal
heterocyclic moiety in selectivity and affinity for α1-
adrenergic versus 5-HT1A receptors, the analogues
with imidazolidine-2,4-dione (hydantoin) moiety,
instead of imidazo[2,1-f]purine-2,4-dione system,
were resynthesized (26). The main goal of the stud-
ies was to assess antiarrhythmic activity of the
selected compounds which may display significant
affinity for α1-adrenergic and serotonin 5-HT1A
receptors. 
EXPERIMENTAL
Chemistry
Structures of the investigated compounds (5-
11) and their syntheses are presented in Scheme 1.
The final derivatives of 1,3-dimethyl-(1H,8H)-imi-
dazo[2,1-f]purine-2,4-dione were obtained within a
reaction of cyclocondensation of 7-acetonyl-8-bro-
motheophylline (1) with appropriate alkylamine
according to the previously reported method (25). 3-
Bromopropyl-5-phenyl-5-alkyl-imidazolidine-2,4-
dione derivatives were condensed with 2-
methoxyphenyl-piperazine yielding the final com-
pounds 12-13 (26). For the purpose of pharmaco-
logical evaluation, all the final compounds were
converted into water-soluble hydrochloride salts.
The structure elucidations of the newly synthesized
compounds were carried out using different spectro-
scopic techniques including 1H NMR and LC/MS.
Further confirmations of the compounds were car-
ried out by elemental analysis (± 0.4%). The ele-
mental analysis data and some physical properties of
these compounds were reported in the experimental
part.
All the chemicals used were commercial prod-
ucts employed without purification. Purity of the
synthesized compounds was confirmed by TLC per-
formed on Merck silica gel 60 F254 aluminum sheets
(Merck, Darmstadt, Germany) with the following
solvents: benzene/acetone/methanol (10 : 10 :10).
Spots were detected by their absorption under UV
light (λ = 254 nm). 1H NMR spectra were recorded
on Varian BB 200 spectrometer at 300 MHz, using
TMS (0.00 ppm) and chloroform-d1, J values are in
hertz (Hz), and splitting patterns are designated as
follows: s (singlet), d (doublet), t (triplet), m (multi-
plet). The LC/MS system consisted of a Waters
Acquity UPLC, coupled to Waters TQD mass spec-
trometer (electrospray ionization mode ESI-tandem
quadrupole). All analyses were carried out using an
Acquity UPLC BEH C18, 50 ◊ 2.1 mm reversed-
phase column. LC/MS data were obtained by scan-
ning the first quadrupole in 0.5 s in a mass range
from 100 to 700 m/z; 8 scans were summed up to
produce the final spectrum. Elemental analyses were
found within ± 0.4% of the theoretical values.
Melting points (m.p.) were determined with a B¸chi
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apparatus and are uncorrected. Column chromatog-
raphy separations were carried out on column with
Merck Kieselgel 60 using the solvents: dichloro-
methane/methanol (90 : 10). 
General procedures for preparation of intermedi-
ate compounds (1-4)
N-aminopropyl derivatives of 2-metoxyphen-
ylpiperazine (2) were obtained according to Gabriel
synthesis of primary alkyl amines in two-step proce-
dure with slight modification (25). Firstly, 2-
metoxy-phenylpiperazine was alkylated with the N-
bromopropylphthalimide (1). Then, after hydrazino-
lysis of 2-1H-isoindole-1,3(2H)-dione, the proper
primary amine was obtained (2). 7-Acetic-8-bro-
motheophylline aldehyde (3) was obtained accord-
ing to the previously described procedure (25). 8-
Acetonyl-8-bromotheophylline (4) was obtained in
the reaction of alkylation of 8-bromotheophylline (1
eq) with chloro-2-propanone (1.1 eq) in boiling ace-
tonitrile, in the presence of K2CO3 (3 eq). After
completion, the precipitate was recrystallized from
absolute ethanol. The results of spectral (1H NMR)
and elemental analysis confirmed the identity of the
compound with obtained by other methods.
General procedures for preparation of final com-
pounds (5-13)
Mixtures of 7-acetonyl-8-bromotheophylline
with a 2-fold excess of appropriate amine in 2-
metoxyethanol, were heated under reflux for 24 h.
After evaporation of the solvent to the brown oil
residues, products were separated by column chro-
matography. 
Compounds 10-13 were resynthesized in a
scale of 100 mg and analytical data for this com-
pounds, were consistent with previously published
ones (25, 26).
7-Methyl-8-[2-N,N-dimetyl-ethyl]-1,3-dimethyl-
(1H,8H)-imidazo[2,1-f]purine-2,4-dione (5)
Yield 87%; m.p. 183-187OC, Rf = 0.27 (A);1H-
NMR (CDCl3, δ, ppm): 2.29 (s, 3H,CH3), 2.33 (ds, J
= 1.1 Hz, 6H, N(CH3)2), 2.71 (t, J = 13.4 Hz, 2H,
CH2CH2N(CH3)2), 3.42 (s, 3H, N3-CH3), 3.58 (s, 3H,
N1-CH3), 4.07 (t, J = 13.4 Hz, 2H, CH2CH2N(CH3)2),
7.13 (s, 1H, C6H); ESI-MS (m/z) 305.35 (M + H) +:
Analysis: calcd. for C14H20N6O2: C, 55.25; H, 6.62;
N, 27.61%; found: C, 55.24; H, 6.63; N, 27.54%.
7-Methyl-8-[2-N,N-dimetyl-propyl]-1,3-dimeth-
yl-(1H,8H)-imidazo[2,1-f]purine-2,4-dione (6)
Yield 69%, m.p. 207-209OC; Rf = 0.32 (A); 1H-
NMR (CDCl3, δ, ppm): 2.29 (s, 3H,CH3), 2.33 (ds, J
= 1.1 Hz, 6H, N(CH3)2), 2.71 (t, J = 13.4 Hz, 2H,
CH2CH2N(CH3)2), 3.42 (s, 3H, N3-CH3), 3.58 (s, 3H,
N1-CH3), 4.07 (t, J = 13.4 Hz, 2H, CH2CH2N(CH3)2),
7.13 (s, 1H, C6H); ESI-MS (m/z) 319.35 (M + H) +:
Analysis: calcd. for C15H22N6O2: C, 56.59; H, 6.96;
N, 26.40; found: C, 56.24; H, 6.93; N, 26.54%.
7-Methyl-8-[2-N,N-diethyl-propyl]-1,3-dimethyl-
(1H,8H)-imidazo[2,1-f]purine-2,4-dione (7)
Yield 80%; m.p. 205-204OC, Rf = 0.38 (A); 1H-
NMR (CDCl3, δ, ppm): 1.48-1.63 (m, 2H,
CH2CH2CH2), 2.39 (s, 3H,CH3), 2.51-2.63 (m, 2H,
CH2CH2CH2), 3.00-3.25 (m, 10H, N(C2H5)2), 3.43
(s, 3H, N3-CH3), 3.56 (s, 3H, N1-CH3), 4.17 (t, J =
13.4 Hz, 2H, CH2CH2CH2), 7.21 (s, 1H, CH); ESI-
MS (m/z): 347.43 (M + H) +; Analysis: calcd. for
C17H26N6O2: C, 58.94; H, 7.56; N, 26.26; found: C,
58.97; H, 7.33; N, 26.20%.
7-Methyl-8-[2-N-morpholinyl-ethyl]-1,3-dimeth-
yl-(1H,8H)-imidazo[2,1-f]purine-2,4-dione (8)
Yield 87%; m.p. 195-196OC; Rf = 0.55 (A); 1H-
NMR (CDCl3, δ, ppm): 2.34 (s, 3H, CH3), 2.50-2.53
(m, 4H, N(CH2)2), 2.7 (t, J = 12.9 Hz, 2H, CH2CH2),
3.42 (s, 3H, N3-CH3), 3.58 (s, 3H, N1-CH3), 3.63-
3.66 (m, 4H, (CH2)2O), 4.08 (t, J = 12.65 Hz, 2H,
CH2CH2), 7.15 (s, 1H, CH) ESI-MS (m/z) 347.38 (M
+ H)+; Analysis: calcd. for C16H22N6O3: C, 55.48; H,
6.40; N, 26.24; found: C, 55.57; H, 6.40; N, 24.42%. 
7-Methyl-8-[2-N-morpholinyl-propyl]-1,3-dimeth-
yl-(1H,8H)-imidazo[2,1-f]purine-2,4-dione (9)
Yield 92%; m.p. 147-149OC; Rf = 0.52 (A); 
1H-NMR (CDCl3, δ, ppm): 2.00-2.09 (m, 2H,
CH2CH2CH2), 2.33-2.41 (m, 9H, CH2N(CH2)2 +
CH3), 3.41 (s, 3H, N3-CH3), 3.57 (s, 3H, N1-CH3),
3.66-3.69 (m, 4H, (CH2)2O), 4.05 (t, J = 12.65 Hz,
2H, CH2CH2CH2), 7.13 (s, 1H, CH) ESI-MS (m/z)
361.41 (M + H)+, Analysis: calcd. for C17H24N6O3: C,
56.65; H, 6.71; N, 23.31; found: C, 56.57; H, 6.70;
N, 23.18%. 
7-Methyl-8-[3-(N4-2í-methoxyphenyl)-piperazin-
N1-yl-propyl]-1,3-dimethyl-(1H,8H)-imidazo[2,1-
f]purine-2,4-dione (10)
Yield 85%, m.p. 195-196OC, Rf = 0.66 (A) 
1H-NMR (CDCl3, δ, ppm): 2.11-2.16 (m, 2H,
CH2CH2CH2), 2.39 (s, 3H, 7CH3) 2.39-2.47 (t, J =
13.3 Hz, 2H, CH2CH2CH2), 2.49-2.67 (m, 4H,
(CH2)2N1), 3.05-3.1 (m, 4H, N4(CH2)2), 3.46 (s, 3H,
N3CH3), 3.63 (s, 3H, N1CH3), 3.89 (s, 3H, OCH3),
4.12-4.16 (t, J = 13.7 Hz, 2H, N8CH2), 6.88-7.07
(m, 4H, H), 7.18 (s, 1H, C6H). ESI-MS (m/z) 466.5
(M + H)+. Analysis: calcd. for C24H31N7O3: C, 61.9;
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H, 6.71; N, 21.06; found: C, 61.72; H, 6.56; N,
20.82%.
8-[3-(N4-2í-Methoxyphenyl)-piperazin-N1-yl-
propyl]-1,3-dimethyl-(1H,8H)-imidazo[2,1-f]pu-
rine-2,4-dione (11)
Yield 73%, m.p. 230-231OC, Rf = 0.67 (A) 
1H-NMR (CDCl3, δ, ppm): 2.12-2.17 (m, 2H,
CH2CH2CH2), 2.45-2.48 (t, J = 13.7 Hz, 2H,
CH2CH2CH2), 2.50-2.68 (m, 4H, (CH2)2N1), 3.13-
3.20 (m, 4H, N4(CH2)2), 3.47 (s, 3H, N3CH3), 3.64
(s, 3H, N1CH3), 3.89 (s, 3H, OCH3), 4.19-4.23 (t, J
= 13.7 Hz, 2H, N8CH2), 6.87-7.07 (m, 5H, H+C7H),
7.43-7.44 (d, J = 2.4 Hz, 1H, C6H). ESI-MS (m/z)
452.5 (M + H+), Analysis: calcd. for C23H29N7O3: C,
61.18; H, 6.47; N, 21.71; found: C, 60.88; H, 6.51;
N, 21.72%.
5-Methyl-5-phenyl-3-[3-(4-(2-methoxyphenyl) pi-
perazin-1-yl)propyl]-imidazolidine-2,4-dione (12)
Yield: 46%; m.p. 156ñ159OC; 1H NMR (300
MHz, (CDCl3, δ, ppm): 1.89ñ1.80 (m, 5H), 2.43ñ
2.35 (t, J = 7 Hz, 2H), 2.62ñ2.54 (m, 4H), 3.10ñ3.01
(m, 4H), 3.64ñ3.55 (t, J = 7 Hz, 2H), 3.88ñ3.82 (s,
3H), 5.56 (s, 1H), 7.03ñ6.81 (m, 4H), 7.51ñ7.33 (m,
5H). Analysis: calcd. for C24H30N4O3: C, 68.22; H,
7.16; N, 13.26; found: C, 67.70; H, 7.24; N, 13.15%.
5-Cyclopropyl-5-phenyl-3-[3-(4-(2-methoxyphenyl)
piperazin-1-yl)propyl]-imidazolidine-2,4-dione (13) 
Yield: 49%; M.p. 148ñ150OC; 1H NMR (300
MHz, (CDCl3, δ, ppm): 0.76ñ0.29 (m, 4H), 1.75ñ
1.64 (m, 1H), 1.91ñ1.80 (t, J = 7 Hz, 2H), 2.47ñ2.39
(m, 2H), 2.66ñ2.58 (m, 4H), 3.11ñ3.02 (m, 4H),
3.62ñ3.56 (t, J = 7 Hz, 2H), 3.87ñ3.83 (s, 3H), 6.01
(s, 1H), 7.02ñ6.82 (m, 4H), 7.60ñ7.32 (m, 5H).
Anal. calcd for C26H32N4O3: C, 69.62; H, 7.19; N,
12.49. Found: C, 69.98; H, 7.34; N, 12.67.
Pharmacology
In vitro binding assay 
Determination of the affinity of the tested com-
pounds at the α1-adrenoreceptors
The affinity of the obtained compounds (5-13)
was evaluated by radioligand binding assays (the
ability to displace [3H]-prazosin from α1) on rat
cerebral cortex. The tissue was homogenized in 20
volumes of ice-cold 50 mM Tris-HCl buffer, pH 7.6
using an Ultra Turrax T25B (IKA) homogenizer.
The homogenate was centrifuged at 20 000 ◊ g for
20 min. The resulting supernatant was decanted and
pellet was resuspended in the same buffer and cen-
trifuged again in the same conditions. The final pel-
let was resuspended in appropriate volume of buffer
(10 mg/1 mL). [3H]prazosin (spec. act. 85 Ci/mM,
Perkin Elmer) was used for labeling α1-receptor.
240 mL of the tissue suspension, 30 mL of 10 µM
phentolamine (displacer), 30 mL of 0.2 nM
[3H]Prazosin and 30 mL of the analyzed compound
were incubated at 30OC for 30 min. The concentra-
tions of analyzed compounds ranged from 10-10 to
10-5 M. The incubation was terminated by rapid fil-
tration over glass fiber filters FilterMate B
(PerkinElmer, USA) using 96-well FilterMate har-
vester (PerkinElmer, USA). Five rapid washes were
performed with ice-cold 50 mM Tris-HCl buffer, pH
7.6. Filter mate was dried in microwave and placed
in plastic bag (PerkinElmer, USA) and soaked in 10
mL of liquid scintillation cocktail Ultima Gold MV
(PerkinElmer, USA). After even distribution of scin-
tillation cocktail filter bag was sealed. The radioac-
tivity on the filter was measured in MicroBeta
TriLux 1450 scintillation counter (PerkinElmer,
USA). All the assays were made in duplicate.
Determination of the affinity of the tested com-
pounds at the 5-HT1A receptor
One millimolar stock solutions of the com-
pounds to be tested were prepared in DMSO. Serial
dilutions of compounds were prepared in 96-well
microplates in assay buffers using an automated
pipetting system (epMotion 5070; Eppendorf).
Radioligand binding was performed using cryopre-
served membranes from cells stably expressing the
relevant human receptor. Reagents and condition:
50 µL working solution of the tested compounds, 50
µL radioligand solution and 150 µL diluted mem-
branes prepared in assay buffer were transferred to
96-well microplates. These were covered with seal-
ing tape, mixed and incubated. The reaction was ter-
minated by rapid filtration through UniFilter 96
GF/B filter microplate and ten rapid washes with
200 µL 50 mM Tris buffer (4OC, pH 7.4) were per-
formed using vacuum manifold and 96-well pipet-
tor. The UniFilter microplates were dried overnight
at 37OC in dry incubator. The UniFilter bottoms
were sealed and 30 µL of liquid scintillator
Betaplate Scint (Perkin Elmer) was added to each
well. The plates were allowed to equilibrate for 1 h
and then radioactivity was counted in MicroBeta
TriLux 1450 scintillation counter (PerkinElmer) at
approximately 30% efficiency. Data were fitted to a
one-site curve-fitting equation with Prism 5
(GraphPad Software) and Ki values were calculated
using the Cheng-Prusoff equation (27). Each com-
pound was tested in eight concentrations from 1 ◊
10-4 M to 1 ◊ 10-11 M (final concentration). All the
assays were carried out in duplicates (n = 2). 
1734 AGNIESZKA ZAG”RSKA et al.
In vivo assay 
Animals
The experiment was carried out on male Wistar
rats (180-220 g). The animals were housed in con-
stant temperature facilities exposed to 12 : 12 light-
dark cycle and maintained on a standard pellet diet
and tap water was given ad libitum. Control and
experimental groups consisted of 6-8 animals each.
The investigated compounds were administered
intravenously (i.v.) in a form of a suspension in 0.9%
physiological saline. Control animals received the
equivalent volume of physiological saline. All pro-
cedures were conducted according to guidelines of
ICLAS (International Council on Laboratory
Animals Science) and approved by The Local Ethic
Committee on Animal Experimentation.
The effect on blood pressure response to methox-
amine
Male Wistar normotensive rats were anes-
thetized with thiopental (75 mg/kg, ip). The right
carotid artery was cannulated with polyethylene
tube filled with heparin in saline to facilitate pres-
sure measurement using the Datamax apparatus
(Columbus Instruments). The tested compounds
were injected in a single dose of 0.5 mg/kg into the
caudal vein after a 5 min stabilization period.
Prophylactic antiarrhythmic activity in adrena-
line-induced arrhythmia
Arrhythmia was evoked in rats anesthetized
with thiopental (60 mg/kg, ip) by an iv injection of
adrenaline (20 µg/kg, in volume of 1 mL/kg) accord-
ing to the method of Szekeres (28). The tested com-
pounds were administered at the doses of 0.25, 0.5, 1
mg/kg iv 15 min before the administration of adren-
aline. The criteria for antiarrhythmic activity were
the lack of premature beats and the inhibition of car-
diac arrhythmia compared to the control group. 
Therapeutic antiarrhythmic activity in adrena-
line-induced arrhythmia
Therapeutic antiarrhythmic activity was deter-
mined according to the method of Szekeres (28).
The arrhythmia was evoked in rats under anesthesia
with thiopental (60 mg/kg, ip) by iv injection of
adrenaline (20 µg/kg, in volume of 1 mL/kg). The
tested compounds were administered at the doses of
0.25, 0.5, 1 mg/kg by iv route at the peak of
arrhythmia, immediately after administration of
adrenaline. The ECG was recorded continuously for
5 min. The criterion of antiarrhythmic activity was
the reduction of premature beats in comparison to
the control group. 
The effect on normal electrocardiogram (ECG)
Electrocardiographic investigations were per-
formed using a Multicard 30 apparatus with stan-
dard lead II and a paper speed of 50 mm/s. The test-
ed compounds were administered intravenously (iv)
at a dose of 1 mg/kg. The ECG was recorded just
before and 1, 5 and 15 min after the administration
of compounds.
Statistical analysis
The data were evaluated by one-way analysis of
variance (ANOVA) followed by Duncan test. The dif-
ference of means was statistically significant if p < 0.05.
RESULTS
According to the aim of this study two series of
1,3-dimethyl-(1H,8H)-imidazo[2,1-f]purine-2,4-
dione and 5,5-disubstituted imidazolidine-2,4-dione
derivatives were obtained and evaluated for their α1
and 5-HT1A affinity by standard competitive dis-
placement assays The affinity data (Ki) of tested
compounds are shown in Table 1. 
The in vitro radioligand binding studies
showed that derivatives of 1,3-dimethyl-(1H,8H)-
imidazo[2,1-f]purine-2,4-dione with alky-
laminealkyl or morpholinylalkyl moieties (5-9) did
not bind at α1 recognition sites. All of the 2-
methoxyphenyl-piperazinyl-propyl derivatives of
1,3-dimethyl-(1H,8H)-imidazo[2,1-f]purine-2,4-
dione and 5,5-disubstituted imidazolidine-2,4-dione
(10-13) were potent α1 receptor ligands with Ki
within the range of 13.9-36.7 nM. Based on this
Figure 2. The effect of compounds 10 and 12 on blood pressure
response to methoxamine (**p < 0.01, *** p < 0.001)
Evaluation of antiarrythmic activity of novel imidazo[2,1-f]purine-2,4-dione... 1735
T
ab
le
 1
. T
he
 c
he
m
ic
al
 s
tr
uc
tu
re
s 
of
 f
in
al
 c
om
po
un
ds
 (
5-
13
) 
an
d 
th
ei
r 
af
fi
ni
ty
 to
w
ar
ds
 α
1-
ad
re
ne
rg
ic
 a
nd
 5
-H
T
1A
re
ce
pt
or
s.
C
om
po
un
d 
C
he
m
ic
al
K
i
[n
M
]
C
om
po
un
d
C
he
m
ic
al
K
i
[n
M
]
no
.
st
ru
ct
ur
es
α 1
5-
H
T
1A
no
.
st
ru
ct
ur
es
α 1
5-
H
T
1A
5
> 
10
00
> 
10
00
1
0
19
.3
 ±
 3
.4
25
.4
 ±
 6
.7
*
6
> 
10
00
> 
10
00
11
36
.7
 ±
 1
.6
16
.8
 ±
 7
.6
*
7
> 
10
00
> 
10
00
1
2
13
.9
 ±
 1
.3
47
.0
 ±
 1
.0
*
8
> 
10
00
> 
10
00
1
3
15
.3
 ±
 1
.4
11
.0
 ±
 1
.0
*
9
> 
10
00
> 
10
00
U
ra
pi
di
l
6.
9 
± 
0.
05
6.
4*
*
*d
at
a 
fr
om
 (
25
, 2
6)
, *
*p
IC
50
va
lu
e.
1736 AGNIESZKA ZAG”RSKA et al.
results, the representatives of both group of com-
pounds 10 and 12, with the highest affinity for α1
receptors, were selected for further pharmacological
in vivo evaluation and their influence on the pressor
responses to methoxamine were studied. It is gener-
ally accepted that α1-ARs antagonists diminish the
pressor response to methoxamine (α1-ARs agonists).
Methoxamine given iv to rats caused a pressor
response at the dose 150 mg/kg. Compounds 10 and
12 given iv in doses of 0.5 mg/kg antagonized the
pressor response elicited by methoxamine (Fig. 2),
thereby exhibited α1-antagonistic properties.
The newly synthesized aminoalkyl derivatives
of 1,3-dimethyl-(1H,8H)-imidazo[2,1-f]purine-2,4-
dione (5-9) did not show affinity for serotonin 5-
HT1A receptor (Table 1). On the contrary, com-
pounds derived from 1,3-dimethyl-(1H,8H)-imida-
zo[2,1-f]purine-2,4-dione with 2-methoxyphenyl-
piperazinyl-propyl moiety (10, 11) displayed high
affinity for 5-HT1A receptors (Table 1) (25).
Furthermore, their counterparts with imidazolidine-
2,4-dione core (12, 13) were also reported as potent
5-HT1A receptor ligands (26).
The selected compounds 10 and 12 with α1-
antagonistic activity were further evaluated for their
antiarrhythmic properties in adrenaline-induced
arrhythmia. These compounds (10, 12) injected
intravenously 15 min before adrenaline, diminished
the occurrence of heart-rhythm disturbances. In the
control group the occurrence of ventricular prema-
ture beats (VBs) and blocks incidence was 100%.
All tested compounds diminished the incidence of
arrhythmia in comparison to the control. Compound
10 diminished the incidence of ventricular prema-
ture beats by 50-33%. Among studied compounds,
the most potent prophylactic antiarrhythmic effect
was produced by compound 12, which significantly
reduced the VBs and blocks incidence of 100% both
at a dose of 0.5 and 1.0 mg/kg (Table 2). In thera-
peutic model of adrenaline-induced arrhythmia, the
compounds 10 and 12 administered intravenously at
the peak of arrhythmia prevented and/or reduced the
number of premature ventricular beats, blocks and
mortality (Table 3). The most potent antiarrhythmic
effect was produced by compound 12, which signif-
icantly reduced the incidence of: ventricular prema-
Table 2. Prophylactic anthiarrhytmic activity in adrenaline-induced arrythmia.
Ventricular
Compound Dose premature Bigeminy Blocks Mortality
no. [mg/kg] beats incidence incidence (%) incidence (%) (%)
(%)
Control - 100 22 100 70
10
0.5 33 17 0 0
1 50 0 0 0
12
0.5 0 0 0 0
1 0 0 0 0
Urapidil
0.5 67 0 100 0
1 50 0 50 0
Table 3. Therapeutic antiarrhythmic activity in adrenaline-induced arrhythmia.
Ventricular
Compound Dose premature Bigeminy Blocks Mortality
no. [mg/kg] beats incidence incidence (%) incidence (%) (%)
(%)
Control - 100 20 100 64
0.25 80 20 100 50
10 0.5 50 0 0 50
1 60 0 0 50
0.06 60 0 40 20
12 0.125 33 0 80 0
0.5 20 0 0 0
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ture beats and mortality at a dose 0,125 mg/kg,
(Table 3). 
The ECG experiments showed that compounds
10 and 12 did not significantly effect on the normal
ECG in anesthetized rats after 15 min after adminis-
tration (Table 4). They did not significantly influ-
ence intervals PR, QRS and QT, as well as the heart
rate after intravenous administration. 
DISCUSSION AND CONCLUSION
The pharmacological in vitro activity of the
investigated compounds (5-13) toward α1 and 5-
HT1A receptors depends mostly on the amine frag-
ment. Introduction of dimethylamine (5, 6), diethy-
lamine (7) and morpholine (8, 9) connected with
imidazo[2,1-f]purine-2,4-dione by 2-3 carbon spac-
er, did not result in significant affinity for α1 as well
as for 5-HT1A receptors. The exchange of alkyl
amine substituents for 2-methoxyphenylpiperazine
moiety (10 and 11) induced affinity for scheduled
receptors. The analysis of the impact of the sub-
stituent in position 7 of imidazo[2,1-f]theophylline,
has shown that the methyl group only slightly
decreased affinity for α1-adrenergic receptor (10 vs.
11). The replacement of heterocyclic fragment,
which can correspond to the HY3-feature of
Barbaroís model, from imidazo[2,1-f]theophylline
to imidazolidine-2,4-dione, caused no significant
changes in receptor activity profile (Table 1).
Moreover, it could be expected that compounds with
LCAPs moiety might displayed dual activity for α1-
AR and 5-HT1AR, and indeed compounds with 2-
methoxyphenyl-piperazinylpropyl fragment (10-13)
showed significant affinity for α1-adrenergic and
serotonin 5-HT1A receptors. It is noteworthy that
among the most active structures, compound 12
exhibited some preference towards α1-adrenergic
receptors, whereas compound 11 slightly stronger
interacted with 5-HT1A receptor site. 
In the next step of the pharmacological evalua-
tion, the selected compounds 10 and 12 as the repre-
sentatives of both heterocyclic system with the highest
α1-adrenergic receptor affinity and α1-adrenolytic
properties were evaluated in vivo for their antiarrhyth-
mic activity in adrenaline-induced arrhythmia model. 
In prophylactic model of adrenaline-induced
arrhythmia, rapid intravenous injection of adrena-
line caused reflex bradycardia (100%), atrioventric-
ular disturbances, extrasystoles (100%), which led
to the death of approximately 70% of animals of the
control group within 15 min of the observation. The
selected compounds were more active in all experi-
ments than reference drug urapidil, especially com-
pound 12, which protected 100% of animals. It is
worth noting, that tested compounds 10 and 12
demonstrated prominent antiarrhythmic activity in
both prophylactic (given iv 15 min before arrhyth-
mogen) and therapeutic (given iv at the peak of
arrhythmia) models of adrenaline-induced arrhyth-
mia. The observed profile of activity allows applica-
tion of such agents not only in prevention, but also
in treatment of acute episodes of arrhythmia.
Moreover, the observed lack of change in the length
of the Q-T interval in ECG experiments, showed
that compounds 10 and 12 did not show potential
proarrhythmic activity. 
The tested compounds 10 and 12 as well as the
reference drug ñ urapidil (6-({3-[4-(2-methoxyphen-
yl)piperazin-1-yl]propyl}amino)-1,3-dimethylpyr-
imidine-2,4(1H,3H)-dione) belong to the class of
LCAPs derivatives. From the pharmacological point of
view, urapidil as α1-adrenolytic, causes a fall in blood
pressure and prevents the expected reflex rise in sym-
pathetic nerve activity. In the previous studies (30-32),
in concentration of 10-6M, urapidil significantly dimin-
ished the occurrence of ventricular tachycardia and
ventricular fibrillation in the isolated rat heart.
Moreover, urapidil revealed also potent prophylactic
and therapeutic antiarrhythmic effect in adrenaline-
induced arrhythmia after intravenous administration
with ED50 values 1.26 and 3.4 mg/kg, respectively. 
The pharmacological results of novel
aminoalkyl derivatives with imidazo[2,1-f]purine-
2,4-dione (10) and imidazolidine-2,4-dione (12)
cores suggest that those antiarrhythmic activity may
be related to their α1-adrenolytic properties. 
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